Convalescent plasma of limited use for COVID-19: study
Leukemia frequently originates from the so-called leukemic stem cell, which resides in a tumor promoting and protecting niche within the bone marrow. Plasma taken from the blood of people who have recovered from COVID-19 and given to people sick with the disease does not reduce their chances of getting seriously ill or dying, new research has found. The findings are from one of the first clinical trials to report the effects of convalescent plasma, which has been given emergency approval in countries including India and the United States.
Plasma taken from the blood of people who have recovered from COVID-19 and given to people sick with the disease does not reduce their chances of getting seriously ill or dying, new research has found. The findings are from one of the first clinical trials to report the effects of convalescent plasma, which has been given emergency approval in countries including India and the United States.
As a potential treatment for patients with moderate COVID-19, particularly in places where laboratory capacity is limited, the study conducted across India and published in the medical journalBMJFriday concluded that "convalescent plasma showed limited effectiveness".
But the researchers said future studies could explore using only plasma with high levels of neutralising antibodies to see if this might be more effective. With few useful treatments and no cure or vaccine, nations are scrambling to find ways to blunt the severity of the new coronavirus.
One idea has been to harvest recovered patients' antibodies, which float in plasma—the liquid component of blood—and then inject this into the blood of someone fighting infection. The technique was first tried against diphtheria in 1892 and was shown to help speed recovery from Ebola and SARS, which is caused by the same family of pathogens as the novel coronavirus.
Observational studies recently carried out suggested convalescent plasma could be beneficial.
But in a randomised clinical trial at dozens of public and private hospitals across India, researchers found that it failed to reduce mortality or stop progression to severe COVID-19 in moderately ill patients.
https://medicalxpress.com/news/2020-10-convalescent-plasma-limited-covid-.html
ارسال به دوستان